All In Biotech

Drug Trial Radar · NCT06684041

A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects

Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study of Multiple Doses of HRS-5965 Capsules in Healthy Subjects and a Phase I Clinical Trial of the Effect of HRS-5965 on QT Interval in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jul 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Nov 9, 2024

Primary completion

Apr 7, 2025

Study completion Apr 7, 2025

Sponsor

Sponsor type
Industry
First posted
Nov 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This was a randomized, double-blind, single-dose, placebo-controlled phase I clinical trial. This study plans to conduct three dose groups of dose 1, dose 2, and dose 3. A total of 32 healthy subjects were planned to be enrolled.

Conditions

  • Hemolytic Anemia

Interventions

  • HRS-5965 capsuleDrug

    HRS-5965 capsule

  • HRS-5965 capsule placeboDrug

    HRS-5965 capsule placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of subjects with adverse events (AEs)Time frame: Baseline up to seven days after the last dosing.
  2. QTcF: Baseline and placebo-adjusted QTcF after oral HRS-5965 capsulesTime frame: Baseline up to 24 hours after dosing.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongnan hospital of Wuhan University

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.